Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inetetamab + pyrotinib + vinorelbine
- Development stage
- Preclinical
- Lead developer
- CITIC Guojian Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination therapy consisting of inetetamab, pyrotinib, and vinorelbine. Pyrotinib is an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor targeting EGFR (HER1), HER2, and HER4, which promotes cellular apoptosis and inhibits cancer cell proliferation by blocking the activation of downstream RAS/RAF/MEK/MAPK and PI3K/AKT signaling pathways. Vinorelbine is a vinca alkaloid chemotherapy drug that works by interfering with microtubules, stopping mitosis and blocking cell division. This combination is likely being investigated for HER2-positive advanced breast cancer.
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)ERBB4 (Erb-b2 receptor tyrosine kinase 4)ERBB2 (Erb-b2 receptor tyrosine kinase 2)Microtubule
Beyond the preview
Go deeper on inetetamab + pyrotinib + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inetetamab + pyrotinib + vinorelbine.